Mammoth Biosciences Raises $45 Million For Crispr Diagnostics—And Its Tech Is Already Being Used Against Coronavirus

Mammoth Biosciences just raised $45 million in Series B funding for their Crispr diagnostics, and they already have several partnerships in the works. The round, led by Decheng Capital and including new investor Verily, brings total funding to over $70 million.